Detection of antibodies to varicella-zoster virus in recipients of the varicella vaccine by using a luciferase immunoprecipitation system assay

Clinical and Vaccine Immunology

Volumn 21, Issue 9, 2014, Pages 1288-1291

  Cohen, Jeffrey I ^a   Ali, Mir A ^a   Bayat, Ahmad ^b   Steinberg, Sharon P ^c   Park, Hosun ^d   Gershon, Anne A ^c   Burbelo, Peter D ^e  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c New York Presbyterian Columbia University Medical Center   (United States)

^d Yeungnam University College of Medicine   (South Korea)

^e NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; GLYCOPROTEIN E; HERPES ZOSTER IMMUNOGLOBULIN; VIRUS CAPSID ANTIGEN; GLYCOPROTEIN GP1, VARICELLA-ZOSTER VIRUS; LUCIFERASE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; FLUORESCENT ANTIBODY TO MEMBRANE ANTIGEN TEST; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN EXPERIMENT; IMMUNOPRECIPITATION; INTERMETHOD COMPARISON; LUCIFERASE ASSAY; LUCIFERASE IMMUNOPRECIPITATION SYSTEM ASSAY; NORMAL HUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; VARICELLA ZOSTER VIRUS; BLOOD; IMMUNOLOGY; PROCEDURES;

ADULT; ANTIBODIES, VIRAL; CHICKENPOX VACCINE; HERPESVIRUS 3, HUMAN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOPRECIPITATION; LUCIFERASES; SENSITIVITY AND SPECIFICITY; VIRAL ENVELOPE PROTEINS;

EID: 84921439461     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00250-14     Document Type: Article

References (13)

1. Williams V, Gershon A, Brunell PA. 1974. Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence. J. Infect. Dis. 130:669-672. http://dx.doi.org/10.1093/infdis/130.6.669.
2. Michalik DE, Steinberg SP, LaRussa PS, Edwards KM, Wright PF, Arvin AM, Gans HA, Gershon AA. 2008. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J. Infect. Dis. 197:944-949. http://dx.doi.org/10. 1086/529043. (Pubitemid 351590021)
3. Saiman L, LaRussa P, Steinberg SP, Zhou J, Baron K, Whittier S, Della-Latta P, Gershon AA. 2001. Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infect. Control Hosp. Epidemiol. 22:279-283. http://dx.doi.org/10.1086/501900. (Pubitemid 32550273)
4. Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, Wells ME, Stephenson WP, Gershon AA. 2000. The postmarketing safety profile of varicella vaccine. Vaccine 19:916-923. http://dx.doi.org/10.1016/S0264-410X(00) 00297-8.
5. Zaia JA, Oxman MN. 1977 Antibody to varicella-zoster virus-induced membrane antigen: immunofluorescence assay using monodisperse glutaraldehyde-fixed target cells. J. Infect. Dis. 136:519-530. http://dx.doi.org/10.1093/infdis/136.4.519. (Pubitemid 8211384)
6. Lafer MM, Weckx LY, de Moraes-Pinto MI, Garretson A, Steinberg SP, Gershon AA, LaRussa PS. 2011. Comparative study of the standard fluorescent antibody to membrane antigen (FAMA) assay and a flow cytometry-adapted (FAMA) assay to assess immunity to varicella-zoster virus. Clin. Vaccine Immunol. 18:1194-1197. http://dx.doi.org/10.1128/CVI.05130-11.
7. Wasmuth EH, Miller WJ. 1990. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J. Med. Virol. 32:189-193. http://dx.doi.org/10.1002/jmv.1890320310.
8. Sauerbrei A, Schafler A, Hofmann J, Schacke M, Gruhn B, Wutzler P. 2012. Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane- antigen test. Clin. Vaccine Immunol. 19:1261-1268. http://dx.doi.org/10.1128/ CVI.00183-12.
9. McDonald SL, Maple PA, Andrews N, Brown KE, Ayres KL, Scott FT, Al Bassam M, Gershon AA, Steinberg SP, Breuer J. 2011. Evaluation of the time resolved fluorescence immunoassay (TRFIA) for the detection of varicella zoster virus (VZV) antibodies following vaccination of healthcare workers. J. Virol. Methods 172:60-65. http://dx.doi.org/10.1016/j.jviromet.2010.12.021.
10. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. 2007. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 56(RR04):1-40.
11. Breuer J, Schmid DS, Gershon AA. 2008. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccines and to screen for susceptibility to varicella. J. Infect. Dis. 197(Suppl 2):S147-S151. http://dx.doi.org/10.1086/529448. (Pubitemid 351590163)
12. Burbelo PD, Hoshino Y, Leahy H, Krogmann T, Hornung RL, Iadarola MJ, Cohen JI. 2009. Serological diagnosis of human herpes simplex virus type 1 and 2 infections by luciferase immunoprecipitation system assay. Clin. Vaccine Immunol. 16:366-371. http://dx.doi.org/10.1128/CVI.00350-08.
13. Kim YH, Hwang JY, Shim HM, Lee E, Park S, Park H. 2014. Evaluation of a commercial glycoprotein enzyme-linked immunosorbent assay for measuring vaccine immunity to varicella. Yonsei Med. J. 55:459-466. http://dx.doi.org/10.3349/ymj. 2014.55.2.459.